Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Ocumetics TechnologyOTCFF -10.83%30 EV-to-EBITDA is -13.32 as of Jul. 31, 2026. GuruFocus rates OTCFF with a GF Score™ of 30/100. The stock has 2 warning signs investors should review. Among 510 Medical Devices & Instruments companies, Ocumetics Technology ranks worse than 196078.24% on this metric.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Ocumetics Technology's enterprise value is $41.54 Mil.
Ocumetics Technology's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was $-3.12 Mil. Therefore, Ocumetics Technology's EV-to-EBITDA for today is -13.32.
The historical rank and industry rank for Ocumetics Technology's EV-to-EBITDA or its related term are showing as below:
OTCFF'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -15.17 Med: 0 Max: 0
Current: -13.32
OTCFF's EV-to-EBITDA is ranked worse than 100% of 510
companies
in the Medical Devices & Instruments industry
Industry Median: 14.265
vs OTCFF: -13.32
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Ocumetics Technology's PE Ratio (TTM) for today is calculated as:
Ocumetics Technology's share price for today is $0.3149.
Ocumetics Technology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.043.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
The historical data trend for Ocumetics Technology's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Ocumetics Technology's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Ocumetics Technology EV-to-EBITDA vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Ocumetics Technology's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Ocumetics Technology's EV-to-EBITDA falls into.
Ocumetics Technology's current Enterprise Value is $41.54 Mil.
Ocumetics Technology's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.12 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Ocumetics Technology (OTCFF) has a EV-to-EBITDA of -13.32 as of Jul. 31, 2026. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Ocumetics Technology. According to the industry distribution chart, Ocumetics Technology ranks #999999 out of 510 companies in the Medical Devices & Instruments industry.
Is Ocumetics Technology's EV-to-EBITDA too high?
Ocumetics Technology's current EV-to-EBITDA is -13.32. Based on the distribution chart, Ocumetics Technology ranks #999999 out of 510 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Ocumetics Technology has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Ocumetics Technology's EV-to-EBITDA compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Ocumetics Technology ranks #999999 out of 510 companies for EV-to-EBITDA. This places Ocumetics Technology in the lower half of its industry. The industry median EV-to-EBITDA is 14.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBITDA for a Medical Devices & Instruments company?
The median EV-to-EBITDA among Medical Devices & Instruments companies is 14.27, based on 510 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBITDA mean?
A high EV-to-EBITDA can signal that a stock is expensive relative to its fundamentals. EV to EBITDA ratio is the company's enterprise value divided by earnings before interest, taxes, depreciation and amortization. View historical data on Ocumetics Technology. For the Medical Devices & Instruments industry, the median EV-to-EBITDA is 14.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Ocumetics Technology's current EV-to-EBITDA is -13.32. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Ocumetics Technology stock overvalued right now?
Ocumetics Technology (OTCFF) has a current EV-to-EBITDA of -13.32. The current EV-to-EBITDA is -13.32. Ocumetics Technology's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBITDA calculated?
EV-to-EBITDA is calculated from a company's financial statements. For Ocumetics Technology (OTCFF), the current EV-to-EBITDA is -13.32 as of Jul. 31, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Ocumetics Technology Corp is a Canadian research and product development company that specializes in adaptive lens designs. The company is engaged in developing an accommodating intraocular lens to eliminate the need for corrective lenses. The company is in the process of developing new lens technology, which is expected to link nerve impulses with the natural mechanisms for accommodation within the human eye.
30GF Score
Get the complete analysis for OTCFF
EV-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OTCFF has been successfully added to your 
